Your browser doesn't support javascript.
loading
The fluctuation of skin perfusion pressure in hemodialysis patients treated with LDL apheresis therapy: A comparison of LDL adsorption and double filtration plasmapheresis.
Yoshimura, Hitoshi; Yoshikawa, Yuki; Noguchi, Yuki; Totani, Teruhiko; Kusuta, Risa; Shimazu, Keiji; Tanaka, Atsuo; Komura, Kazumasa.
Affiliation
  • Yoshimura H; Department of Clinical Engineering, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Yoshikawa Y; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Noguchi Y; Department of Clinical Engineering, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Totani T; Department of Clinical Engineering, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Kusuta R; Department of Nephrology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Shimazu K; Department of Nephrology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Tanaka A; Department of Nephrology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
  • Komura K; Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
J Clin Apher ; 38(4): 362-367, 2023 Aug.
Article in En | MEDLINE | ID: mdl-36367055
ABSTRACT

BACKGROUND:

There have been a number of reports suggesting that LDL apheresis, including LDL adsorption and double filtration plasmapheresis (DFPP), can be applied for the treatment of lower extremity peripheral arterial disease (PAD) in hemodialysis patients, whereas there is no definitive recommendation for the use of LDL apheresis. STUDY

DESIGN:

The change of skin perfusion pressure (SPP) during LDL apheresis was measured in every single treatment to determine the effect of LDL adsorption and DFPP on improving blood flow in lower extremity PAD hemodialysis patients. Eleven hemodialysis patients treated with more than two series of LDL apheresis were involved in the study. "One series" included 10 treatments of LDL apheresis according to the Japanese health care insurance system.

RESULTS:

In total, 320 treatments (32 series) of LDL apheresis were performed utilizing either LDL adsorption or DFPP treatment in 11 patients. The SPP values pre- and post-apheresis were recorded in 315 treatments (228 LDL adsorption and 87 DFPP). The SPP was significantly improved after both LDL adsorption (P < .001) and DFPP (P = .002) treatment. The median change of SPP was significantly larger in the LDL adsorption group (12.6 mm Hg, range -48.5, 77.0 mm Hg) than in the DFPP group (6.7 mm Hg, range -42.0, 72.5 mm Hg) (P = .003). The LDL adsorption consistently offered a significant increase in the SPP, whereas DFPP treatment seemed to have modest effects on the improvement of SPP compared to the LDL adsorption.

CONCLUSIONS:

These data indicate that LDL adsorption should be considered the primary LDL apheresis therapy for lower extremity PAD in hemodialysis patients to achieve improvement of blood flow.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Blood Component Removal / Plasmapheresis Type of study: Guideline Limits: Humans Language: En Year: 2023 Type: Article

Full text: 1 Database: MEDLINE Main subject: Blood Component Removal / Plasmapheresis Type of study: Guideline Limits: Humans Language: En Year: 2023 Type: Article